Inhibition of Galectin-9 sensitizes tumors to anthracycline treatment via inducing antitumor immunity
Authors:
Open Access
- 1 January 2023
- journal article
- research article
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 19 (14) , 4644-4656
Abstract
Anthracyclines are a class of conventionally and routinely used first-line chemotherapy drugs for cancer treatment. In addition to the direct cytotoxic effects, increasing evidence indicates that the efficacy of the drugs also depends on immunomodulatory effects with unknown mechanisms. Galectin-9 (Gal-9), a member of the β-galactoside-binding protein family, has been demonstrated to induce T-cell death and promote immunosuppression in the tumor microenvironment. Here, we asked whether anthracycline-mediated immunomodulatory activity might be related to Gal-9. We found that combining doxorubicin with anti-Gal-9 therapy significantly inhibited tumor growth and prolonged overall survival in immune-competent syngeneic mouse models. Moreover, Gal-9 expression was increased in response to doxorubicin in various human and murine cancer cell lines. Mechanistically, doxorubicin induced tumoral Gal-9 by activating the STING/interferon β pathway. Clinically, Gal-9 and p-STING levels were elevated in the tumor tissues of breast cancer patients treated with anthracyclines. Our study demonstrates Gal-9 upregulation in response to anthracyclines as a novel mechanism mediating immune escape and suggests targeting Gal-9 in combination with anthracyclines as a promising therapeutic strategy for cancer treatment.Keywords
This publication has 53 references indexed in Scilit:
- Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activationScience, 2015
- Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapyNature Medicine, 2014
- Galectin-9 controls the therapeutic activity of 4-1BB–targeting antibodiesJournal of Experimental Medicine, 2014
- Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancerBreast Cancer Research, 2011
- Human Tumor Cells Killed by Anthracyclines Induce a Tumor-Specific Immune ResponseCancer Research, 2011
- Galectins: structure, function and therapeutic potentialExpert Reviews in Molecular Medicine, 2008
- Calreticulin exposure dictates the immunogenicity of cancer cell deathNature Medicine, 2006
- The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunityNature Immunology, 2005
- Doxorubicin induces specific immune functions and cytokine expression in peritoneal cellsCancer Immunology, Immunotherapy, 2003
- Interleukin-1β stimulates galectin-9 expression in human astrocytesNeuroReport, 2001